Astorg has agreed to acquire Thermo Fisher Scientific's microbiology business for over $1 billion, positioning the European buyout firm to capitalize on expanding demand for diagnostic testing in the middle-market pharmacy sector. The deal ranks among the largest private equity investments in diagnostics this year.

Lawyers from Bass, Berry & Sims identified independent and regional pharmacy chains as an underserved segment seeking cost-effective microbiology solutions. Astorg's leadership sees a "wealth of opportunities" to scale the business by deepening relationships with these mid-market customers who have historically relied on larger distribution networks.

The transaction signals renewed private equity appetite for healthcare services businesses that can benefit from operational expertise and focused investment. Mid-market firms are increasingly targeting niche healthcare verticals where specialized knowledge can unlock value, particularly as healthcare delivery decentralizes beyond traditional hospital settings.